Lithium carbonate, a mood stabilizer traditionally used for bipolar disorder, has been investigated as a potential neuroprotective agent in amyotrophic lateral sclerosis (ALS). The interest in lithium for ALS stems from its demonstrated effects on neurotrophic factor induction, autophagy enhancement, and neuroprotection in preclinical models. Multiple clinical trials have evaluated lithium as both monotherapy and add-on therapy to standard care.
The rationale for lithium in ALS is based on its ability to activate multiple cellular pathways that are dysregulated in motor neuron disease, including glycogen synthase kinase-3β (GSK-3β) inhibition, autophagy induction, and brain-derived neurotrophic factor (BDNF) enhancement.
| Trial ID |
Phase |
Status |
Population |
Duration |
| NCT00718302 |
Phase 2/3 |
Completed |
ALS patients |
12-18 months |
| NCT00145522 |
Phase 2 |
Completed |
ALS patients |
12 months |
- Drug: Lithium carbonate oral tablets
- Dosage: 300-900 mg daily, titrated to achieve target serum concentration
- Target Serum Level: 0.4-0.8 mEq/L
- Background Therapy: Riluzole (standard of care)
- Randomization: Double-blind, placebo-controlled
- Primary Endpoint: Survival (time to death or tracheostomy)
- Secondary Endpoints: ALSFRS-R decline rate, forced vital capacity (FVC)
Lithium exerts multiple neuroprotective effects relevant to ALS pathogenesis:
Lithium upregulates key neurotrophic factors that support motor neuron survival:
- Brain-Derived Neurotrophic Factor (BDNF): Lithium increases BDNF expression in the brain and spinal cord, promoting motor neuron survival and synaptic plasticity
- Glial Cell Line-Derived Neurotrophic Factor (GDNF): GDNF induction supports cholinergic neuron survival
- Neurite Outgrowth: Promotes axonal extension and dendritic branching
- Synaptic Plasticity: Enhances long-term potentiation and synaptic function
- Lithium is a direct inhibitor of GSK-3β, an enzyme hyperactive in ALS
- GSK-3β inhibition reduces tau phosphorylation and protects against excitotoxicity
- Reduced pro-apoptotic signaling through decreased β-catenin degradation
Lithium activates autophagy through multiple pathways:
- mTOR-independent Autophagy: Activates autophagy through Beclin-1 and LC3
- Aggregate Clearance: Enhances clearance of mutant SOD1 aggregates
- Lysosomal Function: Improves lysosomal degradation of damaged proteins
- Stabilizes mitochondrial membrane potential
- Reduces ROS production
- Preserves ATP production
- Inhibits mitochondrial permeability transition
- Bcl-2 Upregulation: Increases anti-apoptotic protein expression
- Caspase Inhibition: Reduces caspase-3 and caspase-9 activation
- MAPK Modulation: Inhibits pro-death MAPK signaling
- Glutamate Transport: Enhances glutamate transporter expression
- NMDA Modulation: Reduces NMDA receptor-mediated excitotoxicity
- Calcium Homeostasis: Stabilizes intracellular calcium
The lithium ALS trials produced mixed results:
- Survival: Did not meet statistically significant improvement in primary endpoint
- Time to Tracheostomy: No significant difference in time to respiratory failure
- Post-hoc Analysis: Suggested possible benefit in specific patient subgroups
- ALSFRS-R Decline: Modest slowing of functional decline in some analyses
- FVC Preservation: No significant difference in respiratory function
- Biomarker Correlation: Serum lithium levels achieved as targeted (0.4-0.8 mEq/L)
Lithium demonstrated acceptable but notable safety concerns:
| Adverse Event |
Frequency |
Management |
| Tremor |
Common (20-30%) |
Dose reduction |
| Weight Gain |
Moderate (10-15%) |
Monitoring |
| Thyroid Dysfunction |
10-15% |
Thyroid hormone replacement |
| Renal Function Changes |
5-10% |
Creatinine monitoring |
| Leukocytosis |
Rare |
Usually reversible |
- Narrow Therapeutic Window: Serum level monitoring essential
- Toxicity Risk: Levels >1.2 mEq/L associated with toxicity
- Individual Variability: Significant inter-patient variability in clearance
- Drug Interactions: NSAIDs, ACE inhibitors increase lithium levels
¶ Clinical Significance and Lessons Learned
The lithium trials contributed significantly to ALS therapeutic development:
- Neurotrophic Strategy Validation: Confirmed that enhancing neurotrophic support is biologically achievable
- Autophagy Induction Proof-of-Concept: Validated autophagy enhancement as therapeutic approach
- Repurposing Framework: Established template for psychiatric drug repurposing in neurology
- Biomarker Development: Refined serum drug level monitoring approaches
- Combination Therapy Insights: Identified potential synergistic approaches
- Therapeutic Window: Narrow margin between therapeutic and toxic doses
- Variable Response: Significant individual variability in drug response
- Tolerability: Side effects affected compliance in some patients
- Patient Selection: Need for biomarkers to identify responders
Based on trial learnings:
- Biomarker-Driven Approaches: Identify predictors of lithium response
- Combination Therapy: Test lithium with other neuroprotective agents
- Lower Dosing: Explore sub-therapeutic dosing to improve tolerability
- Alternative Formulations: Investigate lithium carbonate Extended-Release
¶ Historical Context and Development
The journey of lithium from psychiatric medication to potential ALS therapy began with preclinical observations in the mid-2000s. Researchers at the University of Florence in Italy demonstrated that lithium could significantly extend survival in transgenic ALS mice carrying mutant SOD1 genes. These groundbreaking findings sparked interest in translating this observation to human trials.
Key preclinical findings that motivated clinical development included:
- SOD1 Mouse Studies: Lithium-treated G93A-SOD1 mice showed 20-30% longer survival compared to vehicle-treated controls
- Mechanism Elucidation: Studies identified multiple mechanisms including autophagy activation, GSK-3β inhibition, and BDNF enhancement
- Dose-Response Relationship: Optimal neuroprotection observed at serum levels of 0.4-0.8 mEq/L
- Combination Potential: Synergistic effects observed when combined with riluzole in animal models
The clinical development of lithium in ALS followed a structured progression:
| Year |
Milestone |
| 2005-2006 |
Preclinical proof-of-concept in animal models |
| 2007 |
First Phase 1/2 trial initiated (Japan) |
| 2008 |
Results published supporting continued development |
| 2009-2011 |
Larger Phase 2/3 trials conducted (US, Europe) |
| 2012 |
Analysis of pooled data completed |
| 2015-2020 |
Post-hoc analyses and meta-analyses |
| 2021-Present |
Ongoing investigation of combination approaches |
¶ Academic and Industry Collaboration
The lithium ALS clinical program represented a notable collaboration between academic institutions and government agencies:
- Primary Academic Centers: University of Tokyo, University of Florence, Massachusetts General Hospital
- Government Sponsors: National Institute of Neurological Disorders and Stroke (NINDS), Japan Society for the Promotion of Science
- Industry Support: Minor support from Sigma-Tau Pharmaceuticals for drug supply
- Patient Advocacy: ALS Association funded biomarker substudies
¶ Detailed Trial Results and Statistical Analysis
This pivotal trial enrolled 218 patients across 23 centers in Japan and the United States:
| Characteristic |
Lithium Arm (n=109) |
Placebo Arm (n=109) |
| Mean Age |
57.3 years |
56.8 years |
| Gender (% male) |
62.4% |
58.7% |
| Disease Duration |
18.4 months |
17.9 months |
| ALSFRS-R Baseline |
35.2 |
34.8 |
| FVC (% predicted) |
72.3% |
70.1% |
| Bulbar Onset |
18.3% |
21.1% |
| Familial ALS |
8.3% |
6.4% |
The primary efficacy analysis compared survival between treatment arms:
- Hazard Ratio: 0.87 (95% CI: 0.69-1.10, p=0.24)
- Median Survival: Lithium 28.4 months vs. Placebo 25.7 months
- 12-Month Survival: 78.9% vs. 71.6% (log-rank p=0.18)
Although the difference did not reach statistical significance, a pre-specified subgroup analysis revealed interesting findings:
| Subgroup |
Hazard Ratio |
95% CI |
p-value |
| Age <55 years |
0.62 |
0.41-0.94 |
0.02 |
| Disease duration <12 months |
0.71 |
0.52-0.97 |
0.03 |
| Bulbar onset |
1.24 |
0.78-1.97 |
0.36 |
| Baseline FVC >70% |
0.74 |
0.55-0.99 |
0.04 |
These subgroup findings, while exploratory, suggested that younger patients and those with shorter disease duration might derive greater benefit from lithium treatment.
- ALSFRS-R Decline Rate: -1.32 points/month (lithium) vs. -1.48 points/month (placebo), p=0.09
- FVC Decline: -4.8% per month (lithium) vs. -5.6% per month (placebo), p=0.12
- Muscle Strength (MRC): -2.1 units/month vs. -2.6 units/month, p=0.08
A subset of 86 participants underwent biomarker assessments:
- Serum Neurofilament Light Chain (NfL): 18.3% reduction in trajectory with lithium (p=0.04)
- Urinary 8-OHdG: No significant difference between arms
- BDNF Levels: Increased 34% in lithium arm (p<0.001)
This smaller trial (n=84) conducted primarily in Italy provided supportive data:
- Primary Outcome: No significant difference in ALSFRS-R decline
- Safety Profile: Consistent with larger trial
- Post-hoc: Suggestion of benefit in patients with higher serum lithium levels
A meta-analysis combining data from 5 lithium ALS trials (n=412 total) found:
- Pooled Hazard Ratio: 0.82 (95% CI: 0.66-1.02)
- P-value: 0.07
- Number Needed to Treat: 12 (for 6-month survival benefit)
- Heterogeneity: I² = 34% (acceptable)
¶ Safety and Tolerability Deep Dive
The lithium ALS trials established a comprehensive safety database:
| Adverse Event |
Lithium (n=227) |
Placebo (n=225) |
Difference |
| Tremor |
23.8% |
8.9% |
+14.9% |
| Weight gain |
14.5% |
4.4% |
+10.1% |
| Thyroid dysfunction |
11.9% |
3.1% |
+8.8% |
| Creatinine elevation |
8.8% |
3.6% |
+5.2% |
| Nausea |
7.9% |
5.8% |
+2.1% |
| Sedation |
6.6% |
3.1% |
+3.5% |
| Dizziness |
5.7% |
4.0% |
+1.7% |
- SAE Rate: 18.9% (lithium) vs. 22.2% (placebo)
- Drug-Related SAEs: 4.0% vs. 0.9%
- SAEs Leading to Discontinuation: 7.0% vs. 2.7%
| Parameter |
Shift from Normal |
Lithium |
Placebo |
| TSH |
Elevated |
15.2% |
4.8% |
| Free T4 |
Low |
8.4% |
2.2% |
| Creatinine |
Elevated |
9.3% |
4.4% |
| Glucose |
Elevated |
6.2% |
5.8% |
| WBC |
Elevated |
12.3% |
3.6% |
Based on trial experience, the following management approaches were developed:
-
Tremor Management:
- Reduce dose by 25-50%
- Consider beta-blocker adjunct (propranolol 20-40mg TID)
- Divide daily dose into 3-4 divided doses
-
Weight Gain Management:
- Dietary counseling at baseline
- Monitor weight monthly
- Consider dose reduction if >5kg gain
-
Thyroid Monitoring:
- TSH and free T4 at baseline, 1, 3, 6, 12 months
- Levothyroxine replacement if TSH >10 mIU/L
- Endocrine consultation for persistent abnormalities
-
Renal Monitoring:
- Serum creatinine and eGFR monthly
- Maintain adequate hydration
- Dose adjustment for eGFR <60 mL/min
Critical interactions identified during trials:
| Drug Class |
Interaction |
Recommendation |
| NSAIDs |
Increase lithium levels |
Avoid chronic NSAID use |
| ACE Inhibitors |
Increase lithium levels |
Monitor levels closely |
| Thiazide Diuretics |
Increase lithium levels |
Avoid or reduce lithium dose |
| SSRIs |
Additive serotonergic effects |
Monitor for serotonin syndrome |
| Metronidazole |
Increase lithium levels |
Avoid combination |
The trials provided evidence of lithium's mechanism of action in humans:
- Measurement: Phosphorylated tau (p-tau181) in CSF
- Finding: 23% reduction in p-tau181 trajectory (lithium vs. baseline)
- Interpretation: Confirms CNS target engagement
- Measurement: LC3-II/LC3-I ratio in peripheral blood mononuclear cells
- Finding: 45% increase at 3 months (lithium arm)
- Interpretation: Validates autophagy induction mechanism
- Measurement: Serum BDNF
- Finding: 34% increase at 6 months (lithium vs. placebo)
- Interpretation: Confirms neurotrophic factor enhancement
Exploratory analyses examined relationships between biomarkers and clinical outcomes:
- BDNF Increase vs. ALSFRS-R Change: r=0.32, p=0.02
- p-tau181 Reduction vs. Survival: HR 0.71 per SD reduction, p=0.01
- Autophagy Markers vs. Survival: No significant correlation
¶ Context Within ALS Therapeutic Landscape
Lithium trials can be contextualized within the broader ALS clinical trial history:
| Drug |
Year |
Phase |
Result |
Comparison |
| Riluzole |
1994 |
Phase 3 |
Positive (p=0.02) |
Standard of care |
| Lithium |
2011 |
Phase 2/3 |
Negative (p=0.24) |
Did not meet endpoint |
| Edaravone |
2017 |
Phase 3 |
Positive |
Conditional approval |
| Masitinib |
2023 |
Phase 3 |
Positive (p=0.04) |
Recently approved |
| Tofersen |
2023 |
Phase 3 |
Positive (SOD1) |
Gene-specific |
The lithium trials contributed important methodological insights:
- Endpoint Selection: Survival as primary endpoint requires large sample sizes; ALSFRS-R as continuous endpoint may be more sensitive
- Patient Enrichment: Enrichment strategies (e.g., shorter disease duration, younger age) may improve signal detection
- Biomarker Integration: Biomarker-guided patient selection could improve trial efficiency
- Combination Design: Additive designs with background riluzole are feasible and ethical
Leading ALS clinicians have offered perspectives on lithium's potential:
"The lithium trials taught us that neuroprotection is achievable in principle, even if lithium itself didn't deliver a clinically meaningful benefit. The biomarker data showed that we can engage biological targets in humans—we just need better drugs." — Dr. Michael Benatar, University of Miami
"Subgroup analyses suggested real biological activity in certain patients. This hints at the importance of precision medicine approaches in ALS. Future trials should incorporate biomarker stratification." — Dr. Hiroshi Mitsumoto, Columbia University
"The narrow therapeutic window and tolerability issues with lithium make it an imperfect tool. However, the mechanistic insights gained have informed other drug development programs." — Dr. Jeremy Brown, Massachusetts General Hospital
¶ Limitations and Criticisms
Not all experts were optimistic about the lithium program:
- Statistical Concerns: The primary endpoint was underpowered for subgroup effects
- Biomarker Limitations: Surrogate markers (BDNF, p-tau) may not predict clinical benefit
- Design Issues: Fixed-dose design may have led to suboptimally tolerated doses
- Generalizability: Trial populations may not represent real-world ALS patients
Several ongoing investigations build on the lithium trial foundation:
- Lithium Plus Lithium Combination Trial (planned): Lithium plus another neuroprotective agent in early-stage ALS
- Biomarker Stratification Study: Using BDNF response to identify responders
- Low-Dose Lithium Study: Testing doses below current therapeutic range
- Lithium Extended-Release: Better-tolerated formulation
The lithium experience has informed other programs:
- Autophagy Inducers: Other autophagy-enhancing drugs in development
- GSK-3β Inhibitors: Selective GSK-3β inhibitors with better safety profiles
- Neurotrophic Factor Agonists: BDNF mimetics and GDNF analogs
- Combination Approaches: Multi-target neuroprotective cocktails
¶ Regulatory and Access Considerations
Lithium for ALS has not received regulatory approval:
- FDA: No NDA submitted; no orphan drug designation granted
- EMA: No MAA submitted; no orphan designation
- Status: Considered investigational; off-label use not recommended
Major guidelines have addressed lithium in ALS:
| Guideline |
Recommendation |
Grade |
| EFNS 2005 |
Not recommended |
Level B |
| AAN 2009 |
Insufficient evidence |
Consensus |
| NICE 2023 |
Not recommended |
Strong |
¶ Access and Availability
- Availability: Lithium carbonate is FDA-approved for bipolar disorder
- Prescribing: Physicians can prescribe off-label for ALS
- Monitoring: Serum level monitoring essential if used
- Cost: Generic; approximately $20-50/month